Oxcarbazepine Suspension
Product Images NDC 72162-2088

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Oxcarbazepine (NDC 72162-2088). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl721622088)

Label for Oxcarbazepine Oral Suspension, USP 300 mg/5 mL by Bryant Ranch Prepack. Contains storage instructions, dosage strength, volume (250 mL), and manufacturer Amneal Pharmaceuticals LLC. Includes barcode, NDC 72162-2088-2, and advisory to shake well before use and use within 7 weeks of opening.*

FDA Label Image

9f14a9c2-figure-01 (Oxcarbazepine Oral Suspension Usp 1)

Chemical structure diagram of oxcarbazepine showing its molecular framework with two benzene rings, a nitrogen atom, a carbonyl group, and an amide functional group attached.*

FDA Label Image

10 (Oxcarbazepine Oral Suspension Usp 10)

Two-panel instructional illustration showing proper use of a bottle containing oral suspension medication. The first panel depicts a hand shaking the bottle to mix its contents. The second panel shows a hand attaching a dosing syringe to the bottle to withdraw the suspension dose.*

FDA Label Image

10 (Oxcarbazepine Oral Suspension Usp 11)

An instructional illustration showing how to draw liquid medication into a syringe from an oral suspension bottle. It depicts a hand holding the syringe below the bottle with arrows indicating movement upward and downward, and a close-up inset highlighting the syringe dose measurement markings.*

FDA Label Image

10 (Oxcarbazepine Oral Suspension Usp 12)

An instructional illustration showing a hand twisting a syringe to withdraw Oxcarbazepine oral suspension from a bottle. The diagram demonstrates proper technique for drawing medication from the container using the syringe.*

FDA Label Image

10 (Oxcarbazepine Oral Suspension Usp 13)

An instructional illustration showing administration of oral suspension medication. The image depicts a hand holding a syringe to measure oxcarbazepine suspension, then the syringe being used to administer the medication orally to a child's mouth.*

FDA Label Image

9f14a9c2-figure-02 (Oxcarbazepine Oral Suspension Usp 2)

A Kaplan-Meier curve graph comparing exit rates over time (days) from Day 2 to Day 11 between two treatment groups: Oxcarbazepine (solid line) and Placebo (dotted line). The y-axis shows exit rate, and the x-axis shows time on trial in days. The graph includes a log-rank test p-value of 0.0001 indicating a statistical difference between groups.*

FDA Label Image

9f14a9c2-figure-03 (Oxcarbazepine Oral Suspension Usp 3)

A line graph depicting seizure rate over time in days from first dose to first seizure, comparing two treatment groups: Oxcarbazepine (solid line) and Placebo (dotted line). The graph includes a log-rank test p-value of 0.046, showing differences in seizure rates between groups over approximately 140 days.*

FDA Label Image

9f14a9c2-figure-04 (Oxcarbazepine Oral Suspension Usp 4)

A Kaplan-Meier survival curve showing exit rate over time in days for two treatment groups labeled HIGH (solid line) and LOW (dashed line). The vertical axis represents exit rate from 0 to 1, and the horizontal axis represents time to exit in days from 0 to 130. A log-rank test p-value of 0.0001 is noted on the graph.*

FDA Label Image

9f14a9c2-figure-05 (Oxcarbazepine Oral Suspension Usp 5)

A survival plot chart showing exit rates over time in days for two treatment groups labeled HIGH and LOW. The x-axis represents time to exit in days from 0 to 130, and the y-axis represents the exit rate from 0.0 to 1.0. The LOW group (dashed line) shows a faster increase in exit rate than the HIGH group (solid line). The chart includes a log-rank test p-value of 0.0001.*

FDA Label Image

100 (Oxcarbazepine Oral Suspension Usp 6)

Oxcarbazepine 300 mg/5 mL oral suspension in a clear bottle with a white screw cap, shown with a child-resistant safety closure. The image displays the pharmaceutical container without visible labeling information.*

FDA Label Image

10 (Oxcarbazepine Oral Suspension Usp 7)

An instructional diagram showing a syringe with labeled parts: the barrel and the plunger. The barrel is the main cylindrical part with measurement markings, and the plunger is the movable component used to draw in or push out liquid. The image is likely related to dosing or administration instructions for Oxcarbazepine oral suspension.*

FDA Label Image

10 (Oxcarbazepine Oral Suspension Usp 8)

An instructional illustration showing a hand holding a bottle, shaking it side to side. This likely represents how to mix or shake the Oxcarbazepine oral suspension before use.*

FDA Label Image

10 (Oxcarbazepine Oral Suspension Usp 9)

An instructional line drawing showing two hands removing the cap from an oral suspension bottle. An arrow above indicates the direction to pull the cap upward from the bottle top. The bottle cap is placed beside the bottle on a flat surface.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.